Osimertinib as first-line treatment of EGFR mutant advanced non-small-cell lung cancer

被引：9
|
作者：
Liam, Chong-Kin [1 ]
机构：
[1] Univ Malaya, Fac Med, Dept Med, Kuala Lumpur 50603, Malaysia
来源：
TRANSLATIONAL LUNG CANCER RESEARCH | 2017年 / 6卷
关键词：
SINGLE-ARM; AZD9291; MULTICENTER; RESISTANCE; MUTATIONS; ERLOTINIB; TKI;
D O I：
10.21037/tlcr.2017.10.10
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S62 / S66
页数：5
相关论文
共 50 条
  • [1] Osimertinib As First-Line Treatment of EGFR Mutation-Positive Advanced Non-Small-Cell Lung Cancer
    Ramalingam, Suresh S.
    Yang, James C-H
    Lee, Chee Khoon
    Kurata, Takayasu
    Kim, Dong-Wan
    John, Thomas
    Nogami, Naoyuki
    Ohe, Yuichiro
    Mann, Helen
    Rukazenkov, Yuri
    Ghiorghiu, Serban
    Stetson, Daniel
    Markovets, Aleksandra
    Barrett, J. Carl
    Thress, Kenneth S.
    Janne, Pasi A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (09) : 841 - +
  • [2] Osimertinib as First-Line Treatment in EGFR-Mutated Non-Small-Cell Lung Cancer
    Popat, Sanjay
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (02): : 192 - 193
  • [3] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Kao, Hsiang-Fong
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    [J]. FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
  • [4] First-line treatment for advanced non-small-cell lung cancer
    Laskin, Janessa J.
    Sandler, Alan B.
    [J]. ONCOLOGY-NEW YORK, 2005, 19 (13): : 1671 - 1676
  • [5] Osimertinib in first-line treatment of advanced EGFR-mutated non-small-cell lung cancer: a cost-effectiveness analysis
    Aguilar-Serra, Javier
    Gimeno-Ballester, Vicente
    Pastor-Clerigues, Alfonso
    Milara, Javier
    Marti-Bonmati, Ezequiel
    Trigo-Vicente, Cristina
    Alos-Alminana, Manuel
    Cortijo, Julio
    [J]. JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH, 2019, 8 (11) : 853 - 863
  • [6] First-line osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer
    Jeong, Byeong-Ho
    Um, Sang-Won
    [J]. ANNALS OF TRANSLATIONAL MEDICINE, 2018, 6 (03)
  • [7] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Westerink, Lotte
    Nicolai, Jelmer L. J.
    Samuelsen, Carl
    Smit, Hans J. M.
    Postmus, Pieter E.
    Griebsch, Ingolf
    Postma, Maarten J.
    [J]. EUROPEAN JOURNAL OF HEALTH ECONOMICS, 2020, 21 (06): : 931 - 943
  • [8] EGFR TKI as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer
    Nan, Xueli
    Xie, Chao
    Yu, Xueyan
    Liu, Jie
    [J]. ONCOTARGET, 2017, 8 (43) : 75712 - 75726
  • [9] Budget impact of sequential treatment with first-line afatinib versus first-line osimertinib in non-small-cell lung cancer patients with common EGFR mutations
    Lotte Westerink
    Jelmer L. J. Nicolai
    Carl Samuelsen
    Hans J. M. Smit
    Pieter E. Postmus
    Ingolf Griebsch
    Maarten J. Postma
    [J]. The European Journal of Health Economics, 2020, 21 : 931 - 943
  • [10] First-Line Osimertinib in Asian Patients with Advanced EGFR-Mutant Lung Cancer
    Tan, W.
    Chua, B.
    Yin, D.
    Tan, S. H.
    Tan, D.
    Ang, M.
    Kanesvaran, R.
    Jain, A.
    Rajasekaran, T.
    Lai, G.
    Toh, C. K.
    Tan, E.
    Ng, Q. S.
    Lim, W.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S607 - S607
12345